FDA approves Egrifta to treat Lipodystrophy in HIV patients

December 2010
Biomedical Market Newsletter;12/20/2010, p1
The article reports on the approval given by the U.S. Food and Drug Administration (FDA) for the use of Egrifta drug, for the treatment of HIV patients with lipodystrophy. It is reported that, lipodystrophy is a condition in which excess fat develops in different areas of the body due to the antiretroviral drugs used to treat HIV. It is reported that, Egrifta is a growth hormone releasing factor (GRF) drug which is given once-daily through injection.


Related Articles

  • Treatment for growth hormone deficiency. ROSE, VERNA L. // American Family Physician;10/15/1998, Vol. 58 Issue 6, p1484 

    Focuses on sermorelin acetate for injection (Geref), a growth hormone-releasing hormone for the treatment of idiopathic growth hormone deficiency in children, and a complementary product for the diagnosis of growth disorders (Geref Diagnostic) which were approved by the United States Food and...

  • FDA Panel Unanimously Backs Theratechnologies VAT Drug. Young, Donna // BioWorld Today;5/28/2010, Vol. 21 Issue 103, p1 

    This article reports on the decision of the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) to recommend the approval of the drug Egrifta from Theratechnologies Inc. for the treatment of lipodystrophy associated with human immunodeficiency...

  • Tesamorelin: A hope for ART-induced lipodystrophy. Patel, Akash; Gandhi, Hardik; Upaganlawar, Aman // Journal of Pharmacy & Bioallied Sciences;Apr-Jun2011, Vol. 3 Issue 2, p319 

    The article discusses the prevention of lipodystrophy for patients undergoing antiretroviral therapy (ART) through the drug, tesamorelin, which has been approved by the U.S. Food and Drug Administration (FDA) in November 2010. It notes that tesamorelin is contraindicated during pregnancy and for...

  • Metabolic Effects of a Growth Hormone�Releasing Factor in Patients with HIV. Falutz, Julian; Allas, Soraya; Blot, Koenraad; Potvin, Diane; Kotler, Donald; Somero, Michael; Berger, Daniel; Brown, Stephen; Richmond, Gary; Fessel, Jeffrey; Turner, Ralph; Grinspoon, Steven // New England Journal of Medicine;12/6/2007, Vol. 357 Issue 23, p2359 

    Background: Visceral adipose tissue accumulates during antiretroviral therapy in many patients who are infected with the human immunodeficiency virus (HIV); this process is associated with an increased cardiovascular risk. We assessed the use of a growth hormone�releasing factor analogue,...

  • Manipulation of the Growth Hormone Axis in Patients with HIV Infection. Blackman, Marc R. // New England Journal of Medicine;12/6/2007, Vol. 357 Issue 23, p2397 

    The author suggests that data from the study reported in this issue, "Metabolic effects of a growth hormone�releasing factor in patients with HIV," by J. Falutz and colleagues is compelling. He mentions that clinical trials of other therapeutic approaches have been inconclusive in the...

  • Spotlight on Tesamorelinin HIV-Associated Lipodystrophy. Dhillon, Sohita // BioDrugs;2011, Vol. 25 Issue 6, p406 

    Tesamorelin (Egrifta is a synthetic analog of human growth hormone-releasing hormone (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone. It is the first and, so far, only treatment indicated for the reduction of excess abdominal...

  • CME Test.  // Infectious Disease News;Feb2012 Supplement, p19 

    A quiz about the pathogenesis, diagnosis and clinical management of HIV-related lipodystrophy is presented.

  • FDA research uncovers clues on serious diseases.  // FDA Consumer;Mar/Apr98, Vol. 32 Issue 2, p4 

    Presents the results of two studies that may change the way some life-threatening illnesses are treated published by US Food and Drug Administration. Name of the publications in which the results of the study have been published; Medical conditions in which this discovery may have potential...

  • Discovery Pipeline. Ritter, Amy // BioPharm International;Apr2012, Vol. 25 Issue 4, p12 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the first allogenic cell-based therapy, called GINTUIT, which uses cells unrelated to the patient to create the therapeutic.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics